Intermediate for Olaparib. Olaparib (trade name Lynparza) is a PARP inhibitor for the treatment of germline BRCA mutated (gBRCAm) advanced ovarian cancer that has received three or more prior lines of chemotherapy. Olaparib has been approved by the U.S Food and Drug Administration on December 19, 2014.
Product Name: 2-Fluoro-5-((4-oxo-3,4-dihydrophthalazin-1-yl)Methyl)benzoic acid
CAS Number: 763114-26-7
Molecular Weight:  298.2729
Molecular Formula:  C16H11FN2O3
Purity (HPLC): ≥95%
Shipping Conditions: Room temperature.
Storage Conditions: Refrigerated.
Regulatory Statement:  For Research Use Only.